{"name":"BiomX","slug":"biomx","ticker":"PHGE","exchange":"NYSE American","domain":"biomx.com","description":"BiomX is a clinical-stage biotechnology company focused on developing novel phage-based therapies for the treatment of various infectious diseases. The company's lead product, BX-001, is being developed for the treatment of acne and other skin conditions. BiomX has a strong pipeline of phage-based therapies in various stages of development, with a focus on addressing the growing global need for effective and safe treatments for infectious diseases.","hq":"Ness Ziona, Israel","founded":2015,"employees":"~75","ceo":"Jonathan Solomon","sector":"Anti-Infective / Phage Therapy","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"1.3B","metrics":{"revenue":2500000,"revenueGrowth":0,"grossMargin":0,"rdSpend":21292000,"netIncome":-36199000,"cash":4360000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"BX-001 patent cliff ($0.00 at risk)","drug":"BX-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BX004","genericName":"BX004","slug":"bx004","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BX004","genericName":"BX004","slug":"bx004","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-15","type":"earnings","headline":"BiomX Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"BiomX reported its financial results for the fourth quarter and full year 2022, highlighting its progress in advancing its phage-based therapies.","drugName":"","sentiment":"neutral"},{"date":"2022-11-14","type":"deal","headline":"BiomX Announces Collaboration with Merck to Develop Phage-Based Therapies for Infectious Diseases","summary":"BiomX entered into a collaboration with Merck to develop phage-based therapies for the treatment of various infectious diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPellhQlhTWjNqX0VLc0ZNN3pTRkh6dGdpT2tUVXdIa0hQWHBic2FINUJ5Z0FOdXRJZzNjd1h3UmFXZG8ya3hsMzhDMGtOYjVXMENYejctTEZtS0h5ZXUzYm82UlQzTWdISGNITVFhRVBQY3VlQlBTNFMzbFNLOHREbERtUTZ3Rmh1RlZPYVlPMHZWaGVGUU91Q1hXanZiX0hf?oc=5","date":"2026-03-30","type":"pipeline","source":"Stock Titan","summary":"Why a biotech hired a former Mossad deputy as it explores drone defense - Stock Titan","headline":"Why a biotech hired a former Mossad deputy as it explores drone defense","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQXpna1M3OXFaUm9DRDVzUWRnSTFOclJuYVJYYnl4QkRQM1hYQ0dZaUZzQlJmU2tha1VaRWZqWmNxN2ptOFB6OEJZT2pQVjdDRlJfdHotVGNpX1lwR3FjeGI4X2dwQWhvSnI5QXVuM3ZEWEQ0T2VPdG5CRHMwNVZBSkw0LVZfU0swZWR6aXBhTHdZQnMtaURpbTVtdkthUmlzN25Jc1Fiei11cDJCUWlOX1pRZVM2RE94MDBn?oc=5","date":"2026-03-26","type":"pipeline","source":"Stock Titan","summary":"BiomX puts $3M into Israel unit for firefighting drone rights - Stock Titan","headline":"BiomX puts $3M into Israel unit for firefighting drone rights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5TeG54OGVNeHY5YkdDZEhacU9XUGkxenVBcVo3NkRDaVFoT0E1TDRENW1oTENRX1cwVGFrSkFsOS1VM25xZDNpVlNuVFU4WE5GQjVpUG1tVVF5SnBsZzVxYVZyMHFDbnVYX0NMbUt3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Biomx Inc (PHGE) - Stock Titan","headline":"If You Invested $1,000 in Biomx Inc (PHGE)","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-19","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: ANNUAL REPORT","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPY1dfWEQwSm5Ta2JtUFJYV2RRX1liczViTU4yaGI0aDh2TkxrQVBpa3ZycmNWM3F5bjhnSDltXzc1WmVuQjlaa2drNElNZmNXTGdvSVctZldudkpSaFVJWHNueHlmTkhyY0REc2hBc2Vwc2hzRTMxVmxsM0dyM3B4eHlTQ3FGQzg0Z2lNbk03clRCRlpqZ04ydGUyRHR2VGNHZE5JZWdHdV92QXlndFJtbDlNb19FN294bVFmWEEwdDJOOXNWSGdLX3l5UzRaN2RMRmxZNUVBQlJmUkJp?oc=5","date":"2026-01-27","type":"regulatory","source":"Benzinga","summary":"Why Biomx Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket - Benzinga","headline":"Why Biomx Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxPb1hFVmlrZkZ5VFE2RHhhOWpqcl9fMVVQMzVqdXhSdlRuQWlFYkZUcFpNTkRHTlF5M2hMbWFMMkdRaEZNRGN1X2V2OFBveUhHTjJZajdBN2F0QnhRNVA3R2RnWlhjMVRXOFRtNFNiVUJhLUh3djR2OUd0aDBkS2RVNjVmMU9EUWdRQ29FaWdGQnowdE9RaVd3dGdscGhBMDJEbVlpekVGN3Mwdl9lQlBMX0ZObmNNMTZmWEFXTUhkSnY5ckdmZ3RHOE1xZlpzeHRLcF9tazlheDI?oc=5","date":"2026-01-27","type":"pipeline","source":"GlobeNewswire","summary":"BiomX Issues Statement Regarding Recent Common Stock Trading Activity - GlobeNewswire","headline":"BiomX Issues Statement Regarding Recent Common Stock Trading Activity","sentiment":"neutral"}],"patents":[{"drugName":"BX-001","drugSlug":"bx-001","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Phio Therapeutics","Precision BioSciences","Seres Therapeutics"],"therapeuticFocus":["Infectious Diseases","Skin Conditions"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":21292000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-36199000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":4360000,"cashHistory":[],"totalAssets":5783000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}